US grant · National Institutes of Health
NHLBI Early Phase Clinical Trials for Therapeutics and/or Diagnostics for HLBS Disorders (R33 CT Required)
Up to $1,515,000 Closes February 3, 2027
Official listing and how to apply Full funding notice
Source: Grants.gov · Last checked
Key facts
| Funder | National Institutes of Health |
|---|---|
| Part of | Department of Health and Human Services |
| Opportunity number | PAR-25-025 |
| Amount per award | Up to $1,515,000 |
| Opens | December 5, 2024 |
| Closes | February 3, 2027 (85 days left) |
| Who can apply | Schools and universities, Businesses, Government, Nonprofits, Other (see listing), Tribal organizations |
| Applicant types listed | Native American tribal organizations (other than Federally recognized tribal governments); City or township governments; For profit organizations other than small businesses; Others (see text field entitled "Additional Information on Eligibility" for clarification); Public and State controlled institutions of higher education; State governments; Native American tribal governments (Federally recognized); Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education; Small businesses; Independent school districts; Special district governments; Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education; County governments; Private institutions of higher education; Public housing authorities/Indian housing authorities |
| State or area | Nationwide |
| Cost sharing or match | Not required |
| Status | Open |
| Source | Grants.gov |
| Last checked | November 10, 2026 |
About this grant
Summary from the official listing on Grants.gov:
The objective of this funding opportunity is to support investigator-initiated, phase I clinical trials for diagnostic and therapeutic interventions for heart, lung, blood, and sleep (HLBS) disorders in adults and children. The proposed trial can be single or multisite.Applicants applying for funding under this NOFO should be ready to initiate the clinical trial within the first quarter of the project period. Discussion, submission, and attainment of applicable regulatory (FDA, DSMB, IRB) approvals, and establishment of drug (and placebo, if applicable) supplies, and any necessary third-party agreements should be established by the time of award. If time and support for these and other pre-clinical and/or trial readiness activities are desired, applicants should consider the companion NOFO which utilizes an R61/R33 phased approach.
Eligibility
Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Organizations) are not eligible to apply.Non-domestic (non-U.S.) components of U.S. Organizations are eligible to apply.Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
Details are copied from the official source and can change. Check the official listing before you apply. Grant Writing Company is not affiliated with this funder.
Want an expert to write it with you?
Grant Writing Company researches funders, writes organization proposals to each funder's instructions, and checks the package before you submit. experience since 2006. Funders decide every award.